Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Get Free Report) have been given an average rating of “Moderate Buy” by the nine research firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $552.38.
Several analysts recently issued reports on IDXX shares. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research note on Thursday, October 10th. Piper Sandler reaffirmed a “neutral” rating and set a $435.00 target price (down from $520.00) on shares of IDEXX Laboratories in a research note on Monday. BTIG Research began coverage on shares of IDEXX Laboratories in a report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective for the company. JPMorgan Chase & Co. reduced their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Barclays dropped their price target on IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday.
Get Our Latest Report on IDEXX Laboratories
Hedge Funds Weigh In On IDEXX Laboratories
IDEXX Laboratories Stock Up 1.8 %
IDXX stock opened at $423.42 on Monday. The business’s 50-day moving average price is $474.87 and its 200-day moving average price is $485.88. The stock has a market cap of $34.67 billion, a P/E ratio of 40.83, a PEG ratio of 3.61 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. IDEXX Laboratories has a twelve month low of $404.74 and a twelve month high of $583.39.
IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, topping the consensus estimate of $2.69 by $0.11. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. IDEXX Laboratories’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.53 EPS. On average, equities research analysts forecast that IDEXX Laboratories will post 10.45 EPS for the current year.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Recommended Stories
- Five stocks we like better than IDEXX Laboratories
- 3 Healthcare Dividend Stocks to Buy
- What a Trump Win Looks Like for the Market Now and Into 2025
- What is the S&P/TSX Index?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- Financial Services Stocks Investing
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.